|
AU3704101A
(en)
|
2000-02-17 |
2001-08-27 |
Amgen Inc |
Kinase inhibitors
|
|
WO2004009087A1
(en)
|
2002-07-24 |
2004-01-29 |
University Of Cincinnati |
4-4(methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide for treating mutated-ret kinase associated diseases
|
|
CN1925855B
(zh)
|
2003-12-19 |
2010-06-16 |
普莱希科公司 |
开发Ret调节剂的化合物和方法
|
|
US8227455B2
(en)
|
2005-04-18 |
2012-07-24 |
Rigel Pharmaceuticals, Inc. |
Methods of treating cell proliferative disorders
|
|
UA92746C2
(en)
|
2005-05-09 |
2010-12-10 |
Акилайон Фармасьютикалз, Инк. |
Thiazole compounds and methods of use
|
|
WO2006128042A2
(en)
|
2005-05-26 |
2006-11-30 |
The Johns Hopkins University |
Methods of identifying mutations in nucleic acid
|
|
WO2007023382A2
(en)
|
2005-08-25 |
2007-03-01 |
Pfizer Inc. |
Pyrimidine amino pyrazole compounds, potent kinase inhibitors
|
|
WO2007087245A2
(en)
|
2006-01-24 |
2007-08-02 |
Merck & Co., Inc. |
Ret tyrosine kinase inhibition
|
|
CN104706637A
(zh)
|
2006-05-18 |
2015-06-17 |
卫材R&D管理有限公司 |
针对甲状腺癌的抗肿瘤剂
|
|
US20090048214A1
(en)
|
2006-11-15 |
2009-02-19 |
Rigel Pharmaceuticals, Inc |
Methods for Treating Renal Tumors Using 2, 4-Pyrimidinediamine Drug and Prodrug Compounds
|
|
WO2009003136A1
(en)
|
2007-06-26 |
2008-12-31 |
Rigel Pharmaceuticals, Inc. |
Substituted pyrimidine-2, 4 -diamines for treating cell proliferative disorders
|
|
AU2008273889B2
(en)
|
2007-07-09 |
2012-03-08 |
Astrazeneca Ab |
Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
|
|
MY150032A
(en)
|
2007-07-19 |
2013-11-29 |
Merck Sharp & Dohme |
Heterocyclic amide compounds as protein kinase inhibitors
|
|
NZ582879A
(en)
|
2007-07-31 |
2012-03-30 |
Vertex Pharma |
Process for preparing 5-fluoro-1h-pyrazolo [3, 4-b] pyridin-3-amine and derivatives thereof
|
|
WO2009100536A1
(en)
|
2008-02-15 |
2009-08-20 |
Methylgene Inc. |
Inhibitors of kinase activity with 1,2-di-cyclyl substituted alkyne structures
|
|
CA2730190A1
(en)
|
2008-07-14 |
2010-01-21 |
Queen's University At Kingston |
Pharmaceutical compositions comprising ret inhibitors and methods for the treatment of cancer
|
|
JP2012521426A
(ja)
|
2009-03-24 |
2012-09-13 |
Ｍｓｄ株式会社 |
オーロラａ選択的阻害作用を有する新規アミノピリジン誘導体
|
|
BRPI1010887A2
(pt)
|
2009-06-08 |
2016-12-27 |
California Capital Equity Llc |
derivados de triazina e suas aplicações terapêuticas.
|
|
EP2440053A4
(en)
|
2009-06-09 |
2012-10-31 |
California Capital Equity Llc |
BENZYL SUBSTITUTED TRIAZINE DERIVATIVES AND THERAPEUTIC APPLICATIONS THEREOF
|
|
JP2013509444A
(ja)
|
2009-10-30 |
2013-03-14 |
アリアド・ファーマシューティカルズ・インコーポレイテッド |
がんの治療方法及び治療用組成物
|
|
EA024729B1
(ru)
|
2009-11-13 |
2016-10-31 |
Джиноско |
Киназные ингибиторы
|
|
CN103764676A
(zh)
|
2011-08-04 |
2014-04-30 |
日本国立癌症研究中心 |
Kif5b基因和ret基因的融合基因、以及以该融合基因为目标的判断癌症治疗有效性的方法
|
|
BR112014004213A2
(pt)
|
2011-08-23 |
2017-06-20 |
Found Medicine Inc |
novas moléculas de fusão kif5b-ret e usos das mesmas
|
|
CA2846496C
(en)
|
2011-09-02 |
2020-07-14 |
The Regents Of The University Of California |
Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
|
|
US20130096136A1
(en)
|
2011-09-30 |
2013-04-18 |
Methylgene Inc. |
Inhibitors of Protein Tyrosine Kinase Activity
|
|
US10023855B2
(en)
|
2011-10-31 |
2018-07-17 |
Macrogen, Inc. |
Fusion protein comprising C-terminal domain of RET protein and use thereof as a diagnosing marker
|
|
US8841450B2
(en)
|
2011-11-09 |
2014-09-23 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of ATR kinase
|
|
KR20140131955A
(ko)
|
2012-03-09 |
2014-11-14 |
카나 바이오사이언스 인코포레이션 |
신규 트리아진 유도체
|
|
JP2015109806A
(ja)
|
2012-03-22 |
2015-06-18 |
アステラス製薬株式会社 |
新規ｒｅｔ融合体の検出法
|
|
MX360323B
(es)
|
2012-04-25 |
2018-10-29 |
Raqualia Pharma Inc |
Derivados de pirrolopiridinona como bloqueadores de ttx-s.
|
|
AU2013259267A1
(en)
|
2012-05-10 |
2014-11-06 |
Synta Pharmaceuticals Corp. |
Treating cancer with Hsp90 inhibitory compounds
|
|
SG11201500125QA
(en)
|
2012-07-11 |
2015-02-27 |
Blueprint Medicines Corp |
Inhibitors of the fibroblast growth factor receptor
|
|
EP2878672A4
(en)
|
2012-07-26 |
2016-02-17 |
Nat Cancer Ct |
FUSIONSGEN OF CEP55-GEN AND RET-GEN
|
|
JP6513567B2
(ja)
|
2012-09-07 |
2019-05-15 |
エクセリクシス， インク． |
肺腺癌の治療で使用するためのｍｅｔ、ｖｅｇｆｒ、およびｒｅｔの阻害剤
|
|
MY170904A
(en)
|
2012-09-25 |
2019-09-13 |
Chugai Pharmaceutical Co Ltd |
Ret inhibitor
|
|
ES2755772T3
(es)
|
2012-11-07 |
2020-04-23 |
Nerviano Medical Sciences Srl |
Pirimidinil y piridinilpirrolopiridinonas sustituidas, proceso para su preparación y su uso como inhibidores de cinasas
|
|
TWI629266B
(zh)
|
2012-12-28 |
2018-07-11 |
藍印藥品公司 |
纖維母細胞生長因子受體之抑制劑
|
|
KR20150121712A
(ko)
|
2013-02-25 |
2015-10-29 |
브리스톨-마이어스 스큅 컴퍼니 |
Hiv의 치료에 유용한 c-3 알킬 및 알케닐 개질된 베툴린산 유도체
|
|
SMT201700152T1
(it)
|
2013-03-15 |
2017-05-08 |
Glaxosmithkline Ip Dev Ltd |
Derivati piridinici come inibitori della chinasi riarrangiata durante la trasfezione (ret)
|
|
WO2014160521A1
(en)
|
2013-03-15 |
2014-10-02 |
Blueprint Medicines Corporation |
Piperazine derivatives and their use as kit modulators
|
|
IN2013MU00848A
(https=)
|
2013-03-19 |
2015-05-01 |
Glenmark Generics Ltd |
|
|
WO2015006875A1
(en)
|
2013-07-18 |
2015-01-22 |
Methylgene Inc. |
Process for the preparation of substituted pyrimidines
|
|
CN105658814A
(zh)
|
2013-08-20 |
2016-06-08 |
日本国立癌症研究中心 |
在肺癌中检测出的新型融合基因
|
|
SI3057969T1
(sl)
|
2013-10-17 |
2018-10-30 |
Blueprint Medicines Corporation |
Sestavki, uporabni za zdravljenje motenj, povezanih s KIT
|
|
WO2015058129A1
(en)
|
2013-10-17 |
2015-04-23 |
Blueprint Medicines Corporation |
Compositions useful for treating disorders related to kit
|
|
RS63405B1
(sr)
|
2013-10-25 |
2022-08-31 |
Blueprint Medicines Corp |
Inhibitori receptora faktora rasta fibroblasta
|
|
GB201321146D0
(en)
|
2013-11-29 |
2014-01-15 |
Cancer Rec Tech Ltd |
Quinazoline compounds
|
|
US9695165B2
(en)
|
2014-01-15 |
2017-07-04 |
Blueprint Medicines Corporation |
Inhibitors of the fibroblast growth factor receptor
|
|
US9688680B2
(en)
|
2014-08-04 |
2017-06-27 |
Blueprint Medicines Corporation |
Compositions useful for treating disorders related to kit
|
|
WO2016037578A1
(en)
|
2014-09-10 |
2016-03-17 |
Glaxosmithkline Intellectual Property Development Limited |
Novel compounds as rearranged during transfection (ret) inhibitors
|
|
WO2016038552A1
(en)
|
2014-09-10 |
2016-03-17 |
Glaxosmithkline Intellectual Property Development Limited |
Pyridone derivatives as rearranged during transfection (ret) kinase inhibitors
|
|
KR102562866B1
(ko)
|
2014-11-14 |
2023-08-04 |
네르비아노 메디칼 사이언시스 에스.알.엘. |
단백질 키나아제 억제제로서의 6-아미노-7-바이사이클로-7-데아자-퓨린 유도체
|
|
WO2016127074A1
(en)
|
2015-02-06 |
2016-08-11 |
Blueprint Medicines Corporation |
2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors
|
|
CN104844567B
(zh)
|
2015-04-23 |
2017-03-29 |
暨南大学 |
一种中间体1‑(3‑氯‑2‑吡啶基)‑3‑溴‑1h‑5‑吡唑甲酸的合成方法
|
|
BR112018000808A2
(pt)
|
2015-07-16 |
2018-09-04 |
Array Biopharma Inc |
compostos de pirazolo[1,5-a]piridina substituída como inibidores de ret cinase
|
|
CN108026102A
(zh)
|
2015-07-24 |
2018-05-11 |
蓝印药品公司 |
可用于治疗与kit和pdgfr相关的病症的化合物
|
|
BR112018003588A2
(pt)
|
2015-08-26 |
2018-09-25 |
Blueprint Medicines Corp |
compostos e composições úteis para tratamento de distúrbios relacionados ao ntrk
|
|
CN105255927B
(zh)
|
2015-09-30 |
2018-07-27 |
温州医科大学附属第一医院 |
一种kiaa1217-ret融合基因
|
|
EA201891084A1
(ru)
|
2015-11-02 |
2019-10-31 |
|
Антитела к il1rap, биспецифические антигенсвязывающие молекулы, которые связываются с il1rap и cd3, и их применение
|
|
SI3371171T1
(sl)
|
2015-11-02 |
2024-03-29 |
Blueprint Medicines Corporation |
Inhibitorji ret
|
|
US10273281B2
(en)
|
2015-11-02 |
2019-04-30 |
Five Prime Therapeutics, Inc. |
CD80 extracellular domain polypeptides and their use in cancer treatment
|
|
SG10201912607SA
(en)
|
2015-11-19 |
2020-02-27 |
Blueprint Medicines Corp |
Compounds and compositions useful for treating disorders related to ntrk
|
|
MA43416A
(fr)
|
2015-12-11 |
2018-10-17 |
Regeneron Pharma |
Méthodes pour ralentir ou empêcher la croissance de tumeurs résistantes au blocage de l'egfr et/ou d'erbb3
|
|
WO2017145050A1
(en)
|
2016-02-23 |
2017-08-31 |
Glaxosmithkline Intellectual Property Development Limited |
Pyridylpyridone derivative useful as a ret kinase inhibitor in the treatment of ibs and cancer
|
|
US10183928B2
(en)
|
2016-03-17 |
2019-01-22 |
Blueprint Medicines Corporation |
Inhibitors of RET
|
|
MX379513B
(es)
|
2016-04-01 |
2025-03-11 |
Signal Pharm Llc |
Compuestos de aminopurina sustituida, composiciones de estos y métodos de tratamiento con estos.
|
|
WO2017178844A1
(en)
|
2016-04-15 |
2017-10-19 |
Cancer Research Technology Limited |
Heterocyclic compounds as ret kinase inhibitors
|
|
CN109311889B
(zh)
|
2016-04-15 |
2021-11-16 |
缆图药品公司 |
激活素受体样激酶抑制剂
|
|
SI3442535T1
(sl)
|
2016-04-15 |
2023-01-31 |
Cancer Research Technology Limited |
Heterociklične spojine kot zaviralci RET-kinaze
|
|
US10227329B2
(en)
|
2016-07-22 |
2019-03-12 |
Blueprint Medicines Corporation |
Compounds useful for treating disorders related to RET
|
|
WO2018022761A1
(en)
|
2016-07-27 |
2018-02-01 |
Blueprint Medicines Corporation |
Substituted cyclopentane-amides for treating disorders related to ret
|
|
WO2018049233A1
(en)
|
2016-09-08 |
2018-03-15 |
Nicolas Stransky |
Inhibitors of the fibroblast growth factor receptor in combination with cyclin-dependent kinase inhibitors
|
|
JP2018052878A
(ja)
|
2016-09-29 |
2018-04-05 |
第一三共株式会社 |
ピリジン化合物
|
|
CN106749231B
(zh)
|
2016-10-09 |
2019-03-01 |
南京纳丁菲医药科技有限公司 |
萘啶化合物和药物组合物及它们的应用
|
|
TWI704148B
(zh)
|
2016-10-10 |
2020-09-11 |
美商亞雷生物製藥股份有限公司 |
作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
|
|
TWI752098B
(zh)
|
2016-10-10 |
2022-01-11 |
美商亞雷生物製藥股份有限公司 |
作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
|
|
EP3548007A4
(en)
|
2016-12-01 |
2020-08-12 |
Ignyta, Inc. |
METHOD OF TREATMENT OF CANCER
|
|
WO2018136661A1
(en)
|
2017-01-18 |
2018-07-26 |
Andrews Steven W |
SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS
|
|
WO2018136663A1
(en)
|
2017-01-18 |
2018-07-26 |
Array Biopharma, Inc. |
Ret inhibitors
|
|
US11040979B2
(en)
|
2017-03-31 |
2021-06-22 |
Blueprint Medicines Corporation |
Substituted pyrrolo[1,2-b]pyridazines for treating disorders related to KIT and PDGFR
|
|
GB201705971D0
(en)
|
2017-04-13 |
2017-05-31 |
Cancer Res Tech Ltd |
Inhibitor compounds
|
|
JP2020519672A
(ja)
*
|
2017-05-15 |
2020-07-02 |
ブループリント メディシンズ コーポレイション |
ＲＥＴ阻害剤とｍＴＯＲＣ１阻害剤との組合せ及び異常なＲＥＴ活性によって媒介されるがんを処置するためのその使用
|
|
US10934300B2
(en)
|
2017-06-23 |
2021-03-02 |
San Diego State University (Sdsu) Foundation |
Atropisomerism for enhanced kinase inhibitor selectivity
|
|
CN109180677A
(zh)
|
2017-06-30 |
2019-01-11 |
厦门大学 |
取代芳基醚类化合物、其制备方法、药用组合物及其应用
|
|
WO2019008172A1
(en)
|
2017-07-07 |
2019-01-10 |
Nipd Genetics Public Company Limited |
ENRICHED MULTIPLEXED PARALLEL ANALYSIS IN TARGET FOR TUMOR BIOMARKER EVALUATION
|
|
CN107980784B
(zh)
|
2017-12-13 |
2020-05-26 |
中国农业大学 |
5-氨基吡唑类化合物在调节植物生长方面的应用
|
|
LT3728271T
(lt)
|
2017-12-19 |
2022-12-12 |
Turning Point Therapeutics, Inc. |
Makrocikliniai junginiai, skirti ligų gydymui
|
|
EP3740490A1
(en)
|
2018-01-18 |
2020-11-25 |
Array Biopharma, Inc. |
Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors
|
|
JP7060694B2
(ja)
|
2018-01-18 |
2022-04-26 |
アレイ バイオファーマ インコーポレイテッド |
Ｒｅｔキナーゼ阻害剤としての置換ピロロ［２，３－ｄ］ピリミジン化合物
|
|
US11472802B2
(en)
|
2018-01-18 |
2022-10-18 |
Array Biopharma Inc. |
Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors
|
|
CN108341782A
(zh)
|
2018-03-30 |
2018-07-31 |
南京哈柏医药科技有限公司 |
3-氨基-5-甲基吡唑的合成工艺
|
|
PE20210096A1
(es)
|
2018-04-03 |
2021-01-12 |
Blueprint Medicines Corp |
Inhibidor de ret para uso en tratar cancer que tiene una alteracion de ret
|
|
EP3833372A4
(en)
|
2018-08-10 |
2022-06-08 |
Blueprint Medicines Corporation |
TREATMENT OF EGFR MUTANT CANCER
|
|
CN111440151A
(zh)
|
2020-03-25 |
2020-07-24 |
魏威 |
制备抗肿瘤药普拉赛替尼的方法
|
|
CN111362923A
(zh)
|
2020-03-25 |
2020-07-03 |
魏威 |
制备ret抑制剂普拉塞替尼的方法、以及普拉塞替尼的中间体及其制备方法
|
|
EP4157829A1
(en)
|
2020-05-29 |
2023-04-05 |
Blueprint Medicines Corporation |
Solid forms of pralsetinib
|
|
EP4157230A1
(en)
|
2020-05-29 |
2023-04-05 |
Blueprint Medicines Corporation |
Pralsetinib pharmaceutical compositions
|
|
KR20230113612A
(ko)
|
2020-12-04 |
2023-07-31 |
블루프린트 메디신즈 코포레이션 |
프랄세티닙의 제조 방법
|